VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SECZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.
